Asherman’s Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Asherman’s Syndrome Market Outlook

Thelansis’s “Asherman’s Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asherman’s Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Asherman’s Syndrome Overview

Asherman’s syndrome, also known as intrauterine adhesions, arises due to trauma to the basal layer of the endometrium, typically occurring after the curettage of the endometrium following a recent pregnancy. These adhesions can range from minor to severe and impact both menstrual function and fertility. Asherman’s syndrome primarily manifests after dilation and curettage procedures performed for elective termination of pregnancy, missed or incomplete miscarriage, or to treat a retained placenta after delivery. It may occur with or without hemorrhage following delivery or elective termination of pregnancy. In less frequent cases, it may develop after dilation and curettage for non-obstetrical reasons such as excessive bleeding, endometrial cancer sampling, or removal of endometrial polyps. Additionally, it can arise following surgical removal of uterine fibroids. The syndrome occurs when trauma or removal of the basal layer of the endometrium in opposing areas within the uterine cavity occurs. This injury triggers an inflammatory response that leads to adhesive bands forming from one side of the cavity to the other. Notably, abnormalities in placentation, where the placental tissue extends below the basal layer of the endometrium, significantly increase the risk of developing Asherman’s syndrome. The extent of the adhesions determines the severity of the condition, categorized as mild, moderate, or severe. These adhesions can be thin or thick, located sporadically or in a confluent manner. It is important to note that the adhesive bands are typically avascular, which is crucial when discussing treatment options. The American Fertility Society classifies the severity of Asherman’s syndrome into three stages: 1. Mild disease: characterized by a few filmy adhesions affecting less than one-third of the uterine cavity, with normal menstrual cycles or hypomenorrhea. 2. Moderate disease: marked by filmy and dense adhesions involving one-third to two-thirds of the cavity, resulting in hypomenorrhea. 3. Severe disease: characterized by dense adhesions affecting more than two-thirds of the cavity, leading to amenorrhea. Patients with moderate to severe disease have lower chances of conceiving and delivering a healthy pregnancy. However, surgical intervention may improve fertility outcomes if the uterine cavity can be reconstructed and menstrual cycles resume. It is important to note that even after repeated surgeries, restoring a normal endometrial lining may be delayed or not occur at all.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Asherman’s Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034